Dmitry Balyasny’s Vaxcyte PCVX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-514,577
Closed -$29.9M 3385
2026
Q1
$29.9M Buy
514,577
+487,712
+1,815% +$26.5M 0.04% 529
2025
Q4
$1.24M Sell
26,865
-251,268
-90% -$11.2M ﹤0.01% 2089
2025
Q3
$10M Buy
278,133
+173,297
+165% +$5.74M 0.01% 1055
2025
Q2
$3.41M Buy
+104,836
New +$3.44M 0.01% 1481
2024
Q4
Sell
-74,167
Closed -$8.48M 3143
2024
Q3
$8.48M Sell
74,167
-344,548
-82% -$31.1M 0.01% 1033
2024
Q2
$31.6M Buy
+418,715
New +$28.5M 0.06% 445
2022
Q4
Sell
-9,417
Closed -$226K 3122
2022
Q3
$226K Buy
+9,417
New +$239K ﹤0.01% 2279

Other funds holding PCVX

Dmitry Balyasny's PCVX Position: Q2 2026 in Review

Dmitry Balyasny sold out of Vaxcyte (PCVX) in Q2 2026, closing a stake of 514,577 shares — an estimated $29.9M sold.

Dmitry Balyasny first reported a position in PCVX in Q3 2022 and held it in 7 quarters. The position peaked at $31.6M in Q2 2024. 330 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Dmitry Balyasny reported no remaining Vaxcyte position as of Q2 2026 after selling out during the quarter.
  • Dmitry Balyasny sold 514,577 Vaxcyte shares in Q2 2026, an estimated $29.9M.
  • Dmitry Balyasny first reported a position in Vaxcyte in Q3 2022 and held it in 7 quarters.
  • Dmitry Balyasny's Vaxcyte position peaked at $31.6M in Q2 2024.
  • 330 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.